In a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, a new study may help identify which Covid-19 patients with signs of heart injury are at higher risk for death.
A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, the illness caused by the virus.
The U.S. Food and Drug Administration approved Italy-based Cassiopea SpA’s acne treatment Winlevi (clascoterone cream 1%).
Novartis’ Sandoz division will not profit from 15 generic drugs the company is making available to developing countries to treat symptoms of Covid-19 for the pandemic’s duration, the Swiss drugmaker said.
A new $1 billion fund backed by 20 drugmakers including Merck & Co. Inc. and Pfizer Inc. is aiming to bolster struggling antibiotic companies and sustain a pipeline for new treatments.
Finch Therapeutics reported positive topline results from PRISM3, a Phase II trial of CP101, an oral microbiome drug for the prevention of recurrent C. difficile infection.
Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30 days than those who got either drug alone, U.S. researchers reported.
A COVID-19 vaccine candidate under development by China’s CanSino Biologics is moving forward in development after the company published data supporting patient safety.
Foster City, California-based SutroVax closed on a Series D preferred stock financing worth $110 million, which was co-led by new investors RA Capital Management and Janus Henderson Investors.
A lot of attention shifted to the malaria drug hydroxychloroquine for treatment of COVID-19, the disease caused by the novel coronavirus.